Nuclear Medicine and Molecular Imaging最新文献_第9页

A Pictorial Review of I-123 MIBG Imaging of Neuroblastoma Utilizing a State-of-the-Art CZT SPECT/CT System 利用最先进的CZT SPECT/CT系统对神经母细胞瘤I-123 MIBG成像的图像回顾

Nuclear Medicine and Molecular Imaging Pub Date : 2023-09-26 DOI: 10.1007/s13139-023-00825-2

Cassidy Sweet, Natalie Shmuel, Jennifer N. Shoaf, Marcy Stoecklein, Ashok Muthukrishnan, Eli Stern, Nghi C. Nguyen

引用次数: 0

The Biodistribution and Utility of 99mTc-Ethylenedicysteine-Deoxyglucose (99mTc-Glucosamine) in the Identification of Active Disease in Patients with Rheumatoid Arthritis—a Single Center Prospective Study 99mtc -乙炔半胱氨酸-脱氧葡萄糖(99mtc -氨基葡萄糖)在类风湿关节炎患者活动性疾病鉴别中的生物分布和应用——单中心前瞻性研究

Nuclear Medicine and Molecular Imaging Pub Date : 2023-09-25 DOI: 10.1007/s13139-023-00823-4

Osayande Evbuomwan, Barend Jansen Van Rensburg, Gerrit Engelbrecht, Cathryn H. S. Driver, Mathys Labuschagne, Joseph Sempa, Je’nine Horn-Lodewyk

{"title":"The Biodistribution and Utility of 99mTc-Ethylenedicysteine-Deoxyglucose (99mTc-Glucosamine) in the Identification of Active Disease in Patients with Rheumatoid Arthritis—a Single Center Prospective Study","authors":"Osayande Evbuomwan, Barend Jansen Van Rensburg, Gerrit Engelbrecht, Cathryn H. S. Driver, Mathys Labuschagne, Joseph Sempa, Je’nine Horn-Lodewyk","doi":"10.1007/s13139-023-00823-4","DOIUrl":"https://doi.org/10.1007/s13139-023-00823-4","url":null,"abstract":"Abstract Purpose Our objectives were to investigate the utility of 99m Tc-ethylenedicysteine-deoxyglucose (ECDG) in identifying active disease in the joints of patients with rheumatoid arthritis (RA), as well as to evaluate the biodistribution of this radiopharmaceutical. Methods A prospective study was conducted at the Department of Nuclear Medicine of the University of the Free State/Universitas Academic Hospital in Bloemfontein, South Africa. Twenty-two participants from the rheumatology department diagnosed with RA according to the ACR/EULAR classification criteria were enrolled. Participants were injected with 20–25 mCi of 99m Tc-ECDG. Flow, blood pool, whole body, delayed static, and SPECT/CT images were acquired. Known sites of disease were qualitatively assessed for intensity of uptake, and disease severity was graded (Grade 0–3). Results Twenty-two participants were studied. The median (interquartile range) age was 59 (49–68) years, and the majority ( n = 21; 95.5%) were females. There was abnormal increased uptake of 99m Tc-ECDG noted in majority of the sites of known disease, including unknown sites. SPECT/CT imaging localized radiotracer uptake specifically to the synovial space. Similar biodistribution of radiotracer was noted in all patients, irrespective of disease severity or fasting status. Conclusion 99m Tc-ECDG can efficiently assess disease activity in the joints of patients with RA. It accumulates in sites of both clinical and subclinical disease and might be a very useful tool for the rheumatologist in the management of patients with RA.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135816863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Opportunities and Challenges of ChatGPT in Academic Writing: a Roundtable Discussion. 探索ChatGPT在学术写作中的机遇和挑战：圆桌讨论。

IF 1.3

Nuclear Medicine and Molecular Imaging Pub Date : 2023-08-01 Epub Date: 2023-05-23 DOI: 10.1007/s13139-023-00809-2

Hee-Seung Henry Bom

引用次数: 0

Molecular Imaging in Recurrent Prostate Cancer Presented as a Mixed Small Neuroendocrine Tumor/Acinar Adenocarcinoma. 复发性前列腺癌癌症的分子成像表现为神经内分泌小肿瘤/腺泡腺癌。

IF 1.3

Nuclear Medicine and Molecular Imaging Pub Date : 2023-08-01 Epub Date: 2023-04-05 DOI: 10.1007/s13139-023-00800-x

Akram Al-Ibraheem, Dhuha Ali Al-Adhami, Ahmed Saad Abdlkadir, Nabeela Al-Hajaj, Rami Ghanem, Ramiz Abu-Hijlih, Samer Salah

引用次数: 0

¹⁶¹Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer. 161Tb-PSMA释放：癌症前列腺治疗领域有前途的新玩家。

IF 1.3

Nuclear Medicine and Molecular Imaging Pub Date : 2023-08-01 Epub Date: 2023-04-26 DOI: 10.1007/s13139-023-00804-7

Akram Al-Ibraheem, Andrew M Scott

{"title":"161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer.","authors":"Akram Al-Ibraheem, Andrew M Scott","doi":"10.1007/s13139-023-00804-7","DOIUrl":"10.1007/s13139-023-00804-7","url":null,"abstract":"Radiotheranostics with 177Lu-PSMA have changed the treatment paradigm in patients with prostate cancer, becoming the new standard in certain settings. Terbium-161 (161Tb) has been recently investigated as a potential radionuclide for radiotheranostics in various types of cancer, including metastatic castration-resistant prostate cancer (mCRPC). The nuclear medicine team at King Hussein Cancer Center (KHCC) in Amman, Jordan, recently published the first-in-human SPECT/CT imaging results following a well-tolerated dose of 161Tb-PSMA radioligand therapy with no treatment-related adverse events, adding to the potential of radiotheranostics in prostate cancer. Two clinical trials for 161Tb-PSMA radioligand therapy in prostate cancer are currently underway and will provide valuable insights. This review will shed light on the expanding field of radiotheranostics in prostate cancer, which is not without challenges, and will discuss how the introduction of a new therapeutic option like 161Tb-PSMA may help to combat these challenges and build on the proven success of 177Lu-PSMA-based radiotheranostics for the benefit of prostate cancer patients worldwide.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9866167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of an Integrin α_vβ₃ Radiotracer, [¹⁸F]F-FPP-RGD₂, for Monitoring Pharmacological Effects of Integrin α_v siRNA in the NASH Liver. 整合素αvβ3放射性示踪剂[18F]F-FPP-RGD2用于监测整合素αv siRNA在NASH肝脏中的药理学作用的评估。

IF 1.3

Nuclear Medicine and Molecular Imaging Pub Date : 2023-08-01 Epub Date: 2023-03-07 DOI: 10.1007/s13139-023-00791-9

Shuichi Hiroyama, Keiko Matsunaga, Miwa Ito, Hitoshi Iimori, Ippei Morita, Jun Nakamura, Eku Shimosegawa, Kohji Abe

{"title":"Evaluation of an Integrin αvβ3 Radiotracer, [18F]F-FPP-RGD2, for Monitoring Pharmacological Effects of Integrin αv siRNA in the NASH Liver.","authors":"Shuichi Hiroyama, Keiko Matsunaga, Miwa Ito, Hitoshi Iimori, Ippei Morita, Jun Nakamura, Eku Shimosegawa, Kohji Abe","doi":"10.1007/s13139-023-00791-9","DOIUrl":"10.1007/s13139-023-00791-9","url":null,"abstract":"Purpose: Integrin αv is a key regulator in the pathophysiology of hepatic fibrosis. In this study, we evaluated the potential utility of an integrin αvβ3 positron emission tomography (PET) radiotracer, 18F-labeled cyclic arginine-glycine-aspartic acid penta-peptide ([18F]F-FPP-RGD2), for detecting hepatic integrin αv and function in nonalcoholic steatohepatitis (NASH) model rats using integrin αv siRNA.Methods: NASH model rats were produced by feeding a choline-deficient, low-methionine, high-fat diet for 8 weeks. PET/computerized tomography imaging and quantification of integrin αv protein, serum aspartate aminotransferase, and alanine aminotransferase were performed 1 week after single intravenous injection of integrin αv siRNA.Results: Integrin αv siRNA (0.1 and 0.5 mg/kg) dose-dependently decreased hepatic integrin αv protein concentrations in control and NASH model rats. The hepatic mean standard uptake value of [18F]F-FPP-RGD2 was decreased dose-dependently by integrin αv siRNA. The mean standard uptake value was positively correlated with integrin αv protein levels in control and NASH model rats. Serum aspartate aminotransferase and alanine aminotransferase concentrations were also decreased by siRNA injection and correlated with liver integrin αv protein expression levels in NASH model rats.Conclusion: This study suggests that [18F]F-FPP-RGD2 PET imaging is a promising radiotracer for monitoring hepatic integrin αv protein levels and hepatic function in NASH pathology.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9860927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast Metastasis Arising from Ileal Neuroendocrine Tumor: an Unusual Presentation. Ileal神经内分泌肿瘤引起的乳腺转移：一种不寻常的表现。

IF 1.3

Nuclear Medicine and Molecular Imaging Pub Date : 2023-08-01 Epub Date: 2023-02-28 DOI: 10.1007/s13139-023-00792-8

Ritanshu Solanki, Parikshaa Gupta, Ashwani Sood, Bhagwant Rai Mittal

引用次数: 0

Optimization of BMI-Based Images for Overweight and Obese Patients - Implications on Image Quality, Quantification, and Radiation Dose in Whole Body ¹⁸F-FDG PET/CT Imaging. 超重和肥胖患者基于BMI的图像优化——全身18F-FDG PET/CT成像对图像质量、量化和辐射剂量的影响。

IF 1.3

Nuclear Medicine and Molecular Imaging Pub Date : 2023-08-01 Epub Date: 2023-03-20 DOI: 10.1007/s13139-023-00795-5

Yassine Bouchareb, Naima Tag, Hajir Sulaiman, Khulood Al-Riyami, Zabah Jawa, Humoud Al-Dhuhli

{"title":"Optimization of BMI-Based Images for Overweight and Obese Patients - Implications on Image Quality, Quantification, and Radiation Dose in Whole Body 18F-FDG PET/CT Imaging.","authors":"Yassine Bouchareb, Naima Tag, Hajir Sulaiman, Khulood Al-Riyami, Zabah Jawa, Humoud Al-Dhuhli","doi":"10.1007/s13139-023-00795-5","DOIUrl":"10.1007/s13139-023-00795-5","url":null,"abstract":"Purpose: In PET/CT imaging, the activity of the 18F-FDG activity is injected either based on patient body weight (BW) or body mass index (BMI). The purpose of this study was to optimise BMI-based whole body 18F-FDG PET images obtained from overweight and obese patients and assess their image quality, quantitative value and radiation dose in comparison to BW-based images.Methods: The NEMA-IEC-body phantom was scanned using the mCT 128-slice scanner. The spheres and background were filed with F-18 activity. Spheres-to-background ratio was 4:1. Data was reconstructed using the OSEM-TOF-PSF routine reconstruction. The optimization was performed by varying number of iterations and subsets, filter's size and type, and matrix size. The optimized reconstruction was applied to 17 patients' datasets. The optimized BMI-, routine BMI- and the BW-based images were compared visually and using contrast-to-noise ratio (CNR) and standardized uptake values (SUV) measurements.Results: The visual assessment of the optimized phantom images showed better image quality and contrast-recovery-coefficients (CRCs) values compared to the routine reconstruction. Using patient data, the optimized BMI-based images provided better image quality compared to BW-based images in 87.5% of the overweight cases and 66.7% for obese cases. The optimized BMI-based images resulted in more than 50% reduction of radiation dose. No significant differences were found between the three series of images in SUV measurements.Conclusion: The optimized BMI-based approach using 1 iteration, 21 subsets, and 3 mm Hamming filter improves image quality, reduces radiation dose, and provides, at least, similar quantification compared to the BW-based approach for overweight and obese patients.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9860928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidental Detection of Papillary Thyroid Carcinoma in Tc-99 m PSMA Imaging in a Case with Negative FNA Result. 一例FNA阴性病例的Tc-99m PSMA成像中甲状腺乳头状癌的偶然检测。

IF 1.3

Nuclear Medicine and Molecular Imaging Pub Date : 2023-08-01 Epub Date: 2023-02-28 DOI: 10.1007/s13139-023-00793-7

Maryam Abdinejad, Tahereh Ghaedian

引用次数: 0

Algorithm for Reducing Overall Biological Detriment Caused by PET/CT: an Age-Based Study. 减少PET/CT引起的整体生物损害的算法:一项基于年龄的研究。

IF 1.3

Nuclear Medicine and Molecular Imaging Pub Date : 2023-06-01 DOI: 10.1007/s13139-023-00788-4

Marco Spadafora, Pasqualina Sannino, Luigi Mansi, Ciro Mainolfi, Rosario Capasso, Eugenio Di Giorgio, Salvatore Fiordoro, Serena Imbimbo, Filomena Masone, Laura Evangelista

{"title":"Algorithm for Reducing Overall Biological Detriment Caused by PET/CT: an Age-Based Study.","authors":"Marco Spadafora, Pasqualina Sannino, Luigi Mansi, Ciro Mainolfi, Rosario Capasso, Eugenio Di Giorgio, Salvatore Fiordoro, Serena Imbimbo, Filomena Masone, Laura Evangelista","doi":"10.1007/s13139-023-00788-4","DOIUrl":"https://doi.org/10.1007/s13139-023-00788-4","url":null,"abstract":"Purpose: This study is to use a simple algorithm based on patient's age to reduce the overall biological detriment associated with PET/CT.Materials and methods: A total of 421 consecutive patients (mean age 64 ± 14 years) undergoing PET for various clinical indications were enrolled. For each scan, effective dose (ED in mSv) and additional cancer risk (ACR) were computed both in a reference condition (REF) and after applying an original algorithm (ALGO). The ALGO modified the mean dose of FDG and the PET scan time parameters; indeed, a lower dose and a longer scan time were reported in the younger, while a higher dose and a shorter scan time in the older patients. Moreover, patients were classified by age bracket (18-29, 30-60, and 61-90 years).Results: The ED was 4.57 ± 0.92 mSv in the REF condition. The ACR were 0.020 ± 0.016 and 0.0187 ± 0.013, respectively, in REF and ALGO. The ACR for the REF and ALGO conditions were significantly reduced in males and females, although it was more evident in the latter gender (all p < 0.0001). Finally, the ACR significantly reduced from the REF condition to ALGO in all three age brackets (all p < 0.0001).Conclusion: Implementation of ALGO protocols in PET can reduce the overall ACR, mainly in young and female patients.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10296945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0